

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

GILEAD SCIENCES, INC.,

Plaintiff,

v.

APOTEX, INC., LUPIN LIMITED,
LAURUS LABS LIMITED, SHILPA
MEDICARE LIMITED, SUNSHINE
LAKE PHARMA CO., LTD., NATCO
PHARMA LIMITED, CIPLA LIMITED,
MACLEODS PHARMACEUTICALS
LTD., HETERO USA INC., HETERO
LABS LIMITED UNIT-V, AND HETERO
LABS LIMITED,

Defendants.

C.A. No. 20-00189 (MN)

STIPULATION AND ORDER

WHEREAS, on August 15, 2022, the parties filed under seal their [Proposed] Joint Pretrial Order (D.I. 460).

WHEREAS, attached to the [Proposed] Joint Pretrial Order as Exhibit 10C was Defendants' list of contested trial exhibits.

WHEREAS, the Court held a pretrial conference on August 29, 2022.

WHEREAS, on September 2, 2022, the Court entered an Order adopting the [Proposed] Joint Pretrial Order as modified by any discussion at the pretrial conference [D.I. 466].

WHEREAS, since the submission of the parties' [Proposed] Joint Pretrial Order, Defendants have made some amendments to their list of contested trial exhibits that was originally submitted as Exhibit 10C to the [Proposed] Joint Pretrial Order. These amendments include corrections to typographical errors in entries for DTX-147 and DTX-202. Defendants' amended trial exhibit list is annexed hereto as Attachment A.

THEREFORE, IT IS HEREBY STIPULATED AND AGREED, by and between the undersigned attorneys and subject to the approval of the Court, that Defendants' amended trial exhibit list annexed hereto as Attachment A shall be substituted for Exhibit 10C to the [Proposed] Joint Pretrial Order.

Dated: September 9, 2022

/s/Grayson P. Sundermeir

Douglas E. McCann (#3852)
Grayson P. Sundermeir (#6517)
Fish & Richardson P.C.
222 Delaware Avenue, 17th Floor
Wilmington, DE 19801
dmccann@fr.com;
sundermeir@fr.com

Attorneys for Plaintiff
Gilead Sciences, Inc.

/s/Adam W. Poff

Adam W. Poff (#3990)
YOUNG CONAWAY STARGATT
& TAYLOR, LLP
Rodney Square
1000 North King Street
Wilmington, DE 19801
(302) 571-6642
apoff@ycst.com


Attorney for Defendants
Hetero Labs Limited, Hetero USA, Inc., and
Hetero Labs Ltd. Unit V

/s/James S. Green Jr.

James S. Green, Jr. (#4406)
SEITZ, VAN OGTROP & GREEN, P.A.
222 Delaware Avenue, Suite 1500
P.O. Box 68
Wilmington, DE 19899
(302) 888-0600
jsgreen@svglaw.com

Attorneys for Defendant
Cipla Limited

SO ORDERED this 12th day of September 2022.


The Honorable Maryellen Noreika
United States District Judge

ATTACHMENT A

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-001	Defendants' Notice of Deposition of Sonja Tong		
DTX-002	Notice of Deposition of Gilead Sciences, Inc. Pursuant to F.R.C.P. 30(b)(6)		
DTX-003	FDA Correspondence to Gilead Sciences, Inc. re NDA 208351	GILEAD_TAF00437238	GILEAD_TAF00437287
DTX-004	FDA Correspondence to Gilead Sciences, Inc. re NDA 208351	GILEAD_REGTAF00113569	GILEAD_REGTAF00113618
DTX-005	Highlights of Prescribing Information - ODEFSEY (09/2021)		
DTX-006	FDA Correspondence to Gilead Sciences, Inc. re NDA 208215	GILEAD_TAF00474550	GILEAD_TAF00474584
DTX-007	Highlights of Prescribing Information - DESCovy (09/2017)	GILEAD_TAF00807914	GILEAD_TAF00807943
DTX-008	FDA Correspondence to Gilead Sciences, Inc. re NDA 208215	GILEAD_REGTAF00440213	GILEAD_REGTAF00440258
DTX-009	Highlights of Prescribing Information - DESCovy (09/2021)		
DTX-010	FDA Correspondence to Gilead Sciences, Inc. re NDA 208464	GILEAD_TAF02085062	GILEAD_TAF02085096
DTX-011	Highlights of Prescribing Information - VEMOLIDY (09/2021)		
DTX-012	Email from E. Berglund to L. Frenz and S. Tong RE: ODEFSEY Approval Timing	GILEAD_TAF00437235	GILEAD_TAF00437236
DTX-013	Email from J. Hilton to S. Tong et al. RE: Paul Sax on DVY	GILEAD_TAFO1826697	GILEAD_TAFO1826698
DTX-014	Email from S. Tong to P. Tomkins FW: TAF MoA & PK - updated	GILEAD_TAF00414087	GILEAD_TAF00414091
DTX-015	Attachment to Email from S. Tong to P. Tomkins FW: TAF MoA & PK - updated	GILEAD_TAF00414092	GILEAD_TAF00414092
DTX-016	Email from S. Tong to P. Tomkins RE: TAF MoA & PK - updated	GILEAD_TAF00414099	GILEAD_TAF00414104
DTX-017	Email from P. Tomkins to S. Tong RE: F/TAF Indications: Limitations of Use Statement	GILEAD_TAF02081376	GILEAD_TAF02081380
DTX-018	Original VIREAD® Label	TAF_THIO_00000055	TAF_THIO_00000074
DTX-019	2009 VIREAD® Label	NAT-TAF-018333	NAT-TAF-018376
DTX-020	2009 TRUVADA® Label	NAT-TAF-017689	NAT-TAF-017721
DTX-021	Original ATRIPLA® Label	TAF_THIO_00000075	TAF_THIO_00000124
DTX-022	Original HEP SERA™ Label	TAF_THIO_00000125	TAF_THIO_00000146
DTX-023	Eisen, S. A., Miller, D. K., Woodward, R. S., Spitznagel, E., & Przybeck, T. R. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Archives of internal medicine, 150(9), 1881-1884.	TAF_THIO_00000147	TAF_THIO_00000150
DTX-024	Thio CL, Sulkowski MS, Thomas DL. Treatment of HIV-HBV Co-infection: thinking outside the black box. Clin Inf Dis 2005, Oct 1;41(7):1035-40	TAF_THIO_00000151	TAF_THIO_00000156

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-025	Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, Thio C, Benhamou Y. Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel AIDS 2004, 19(3):221-40	TAF_THIO_00000157	TAF_THIO_00000176
DTX-026	Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy. 2009 Oct 29(10):1212-27	TAF_THIO_00000177	TAF_THIO_00000192
DTX-027	Curriculum Vitae of Dr. Chloe L. Thio, M.D.		
DTX-028	BARACLUDE® Label	TAF_THIO_00000259	TAF_THIO_00000296
DTX-029	BIKTARVY® Label	TAF_THIO_00000193	TAF_THIO_00000236
DTX-030	Hill et al., "Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Is There a True Difference in Efficacy and Safety?," J. of Virus Eradication 4: 72-79 (2018)	LUP-TEN0287275	LUP-TEN0287282
DTX-031	Pilkington et al., "Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate: An Updated Meta-Analysis of 14,894 Patients Across 14 Trials," AIDS 34:2259-2268 (2020)	LUP-TEN0287283	LUP-TEN0287293
DTX-032	Surial B et al., "Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: A cohort study." Ann Intern Med 2021 Mar 16 [epub]	TAF_THIO_00000245	TAF_THIO_00000258
DTX-033	Mallon et al., "Lipid Changes After Switch from TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides," Open Forum Infectious Diseases, Volume 9, Issue 1 (2022)	TAF_THIO_00000237	TAF_THIO_00000244
DTX-034	Plaintiff Gilead Sciences, Inc.'s Objections and Responses to Defendants' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)		
DTX-035	Gilead letter - IND 63,737 Serial No. 019 for GS 7340-02 Information Amendment: Clinical Study Report Summary	GILEAD_TAF01710216	GILEAD_TAF01710235
DTX-036	U.S. Patent No.: US 7,390,791 B2	GILEAD_TAF00778939	GILEAD_TAF00778963
DTX-037	Interoffice Memorandum, Subject: PMPA Amidate Prodrug (GS 7340): Rationale for Development	GILEAD_TAF00721606	GILEAD_TAF00721606.0018

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-038	Interoffice Memorandum, Subject: Summary of Tissue Distribution, Excretion and Pharmacokinetics of [14-C] Labeled GS 7340-2, Monoamide Prodrug of Tenofovir, Following Oral Administration to Dogs: Comparison to GS 4331	GILEAD_TAF00721327	GILEAD_TAF00721331
DTX-039	Interoffice Memorandum, Subject: LC/MS Determination of PMPA and GS 7171 in Dog PMBC Samples	GILEAD_TAF00228229	GILEAD_TAF00228229
DTX-040	Interoffice Memorandum, Subject: Supplement to the Minutes from Prodrug Meeting at 05/21/99	GILEAD_TAF00059842	GILEAD_TAF00059847
DTX-041	Email, Subject: PMPA prodrugs	GILEAD_TAF00226253	GILEAD_TAF00226253
DTX-042	Interoffice Memorandum, Subject: Back-up candidate for Tenofovir DF; status of amide prodrug	GILEAD_TAF00776335	GILEAD_TAF00776341
DTX-043	Interoffice Memorandum, Subject: GS 7340-2 IND Selection	GILEAD_TAF00073465	GILEAD_TAF00073471
DTX-044	Interoffice Memorandum, Subject: Potential IND Selection for GS 7340-2	GILEAD_TAF00201810	GILEAD_TAF00201838
DTX-045	Nucleotide Round Table 9/12/00	GILEAD_TAF00234988	GILEAD_TAF00234992
DTX-046	GS 7340 Preliminary Commercial Recommendation August 19, 2002	GILEAD_TAF01674683	GILEAD_TAF01674690
DTX-047	Email, Subject: GS7340 CMC Dev. Plan	GILEAD_TAF00761884	GILEAD_TAF00761888
DTX-048	Email, Subject: GS7340 Base Case Forecast Assumptions	GILEAD_TAF00236764	GILEAD_TAF00236765
DTX-049	Email, Subject: GS 7340 Business Review	GILEAD_TAF00762050	GILEAD_TAF00762065
DTX-050	Letter from Bernard M. Wagner, M.D. September 15, 2003	GILEAD_TAF00228298	GILEAD_TAF00228304
DTX-051	2003 Memo	GILEAD_TAF02010607	GILEAD_TAF02010614
DTX-052	Email, Subject: FW: 2004-03-01 GS 7340 for HIV Strategy.ppt	GILEAD_TAF02012379	GILEAD_TAF02012390
DTX-053	Email, HIV Franchise Strategy Updated Document	GILEAD_TAF02012402	GILEAD_TAF02012412
DTX-054	Gilead Project Management - GS 7340 Critical Activity Status Report September 2004	GILEAD_TAF02010615	GILEAD_TAF02010635
DTX-055	Gilead Sciences Strategic Update Board of Directors November 3, 2004	GILEAD_TAF00060560	GILEAD_TAF00060600
DTX-056	Email, Subject: Scientific Committee	GILEAD_TAF01699762	GILEAD_TAF01699765
DTX-057	Board of Directors Strategic Planning Meeting October 25, 2006	GILEAD_TAF02240752	GILEAD_TAF02240761
DTX-058	Email, Subject: FW: API Cost	GILEAD_TAF00233334	GILEAD_TAF00233334
DTX-059	Email, Subject: RE: Gilead Daily Analyst Reports and Information Packet 05.13.10	GILEAD_TAF00237428	GILEAD_TAF00237431
DTX-060	Email, Subject: RE: Portfolio Review Day 1	GILEAD_TAF02012004	GILEAD_TAF02012004
DTX-061	GS-7340: TAF "The Short Story" 1996 - 2004	GILEAD_TAF00225945	GILEAD_TAF00225945
DTX-062	Email, Subject: RE: Understand 7340 Assumptions	GILEAD_TAF01652101	GILEAD_TAF01652102
DTX-063	Rebuttal Expert Report of Bernhardt L. Trout, Ph.D.		

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-064	Notebook No. 1509, Issued to Terhorst	GILEAD_TAF01704350	GILEAD_TAF1704461
DTX-065	Gilead Technical Report, Report No. PR-14-15351 (1.0), 31 Jul 2014	GILEAD_TAF01509207	GILEAD_TAF 01509248
DTX-066	U.S. Patent No. 8,754,065	GILEAD_TAF00006970	GILEAD_TAF00006984
DTX-067	Pharmorphix, Polymorphism Studies on GS-7340 Hemi-Fumarate for Gilead Sciences Inc.		
DTX-068	Gilead Offers Voluntary Licenses For Manufacturing of Viread in Developing World	APO-TEN-Stephenson 000537	APO-TEN-Stephenson 000537
DTX-069	Gilead Announces New Agreement With Medicines Patent Pool for Access to Medicines in Developing World Countries, July 24, 2014	APO-TEN-Stephenson 000535	APO-TEN-Stephenson 000536
DTX-070	"Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue," W.A. Lee, et al., Antimicrobial Agents and Chemotherapy, May 2005, pp. 1898-1906	DEFS-TAF-000926	DEFS-TAF-000934
DTX-071	IND 63,737 for GS-7340-02, Gilead Information Amendment: Clinical Study Report Summary, 3/31/05	GILEAD_TAF01710216	GILEAD_TAF01710235
DTX-072	International Patent Publication Number WO 2008/143500	DEFS-TAF-000827	DEFS-TAF-000877
DTX-073	"Characterization and Anisotropic Lattice Expansion/Contraction of Polymorphs of Tenofovir Disoproxil Fumarate," E.U. Lee, et al., Crystal Growth & Design, 2010, Vol. 10, 2314-2322	DEFS-TAF-000980	DEFS-TAF-000988
DTX-074	Rebuttal Expert Report of David Piontkowsky, M.D.		
DTX-075	Gilead Sciences Commences Human Clinical Testing of Systemic PMPA for HIV, October 17, 1996		
DTX-076	Gilead Sciences Announces Termination of Its U.S. Development Program for Adefovir Dipivoxil for HIV, December 3, 1999		
DTX-077	Gilead Sciences Potential Future of HIV Treatment	GILEAD_TAF02548468	GILEAD_TAF02548484
DTX-078	Reply Expert Report of Dr. Chloe Lynne Thio, M.D.		
DTX-079	Plaintiff Gilead Sciences, Inc.'s Objections and Responses to Defendants' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)		
DTX-080	Excel Spreadsheet Koomey02-GILEAD_TA0227669.xlsx	GILEAD_TAF0227669	
DTX-081	Gilead 2017 FPOA Executive Summary Roll Out	GILEAD_TAF00379090	GILEAD_TAF00379150
DTX-082	HIV Community 2015: Considering TAF in the "Real World"	GILEAD_TAF02330670	GILEAD_TAF02330693
DTX-083	Email Subject Re: FSS Pricing Recommendation	GILEAD_TAF01801773	GILEAD_TAF01801776

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-084	Excel Spreadsheet Koomey06-GILEAD_TAF01801777.xls	GILEAD_TAF01801777	
DTX-085	Gilead Science TAF: Findings from the field Raising PT to \$67 on positive doc feedback on TAF	GILEAD_TAF00564457	GILEAD_TAF00564491
DTX-086	HIV Business Unit Breakfast - 2017, June 23, 2017	GILEAD_TAF01984618	GILEAD_TAF01984645
DTX-087	Gilead Regulatory Affairs Advertising and Promotion	GILEAD_TAF00463727	GILEAD_TAF00463730
DTX-088	HIV BU Buy-Up Recommendations, Presentaion to Laura Hamill	GILEAD_TAF01986000	GILEAD_TAF01986045
DTX-089	US HIV BU Overview HIV Day, March 21st Melissa Koomey Vice President Draft	GILEAD_TAF01982945	GILEAD_TAF01983021
DTX-090	HIV Business Unit Review for Laura Hamill	GILEAD_TAF01985815	GILEAD_TAF01985847
DTX-091	Expert Report of Julie L. Davis		
DTX-092	Copy of the Orange Book, 22nd Edition		
DTX-093	CV of Chris Meier, Ph.D.		
DTX-094	US Patent 4,808,716 Holy and Rosenberg	TAF_MEIER000288	TAF_MEIER000293
DTX-095	US Patent 5,798,340 Bischofberger	DEFS_TAF_000305	DEFS_TAF_000366
DTX-096	US Patent 6,057,305 Holy	TAF_MEIER000463	TAF_MEIER000480
DTX-097	US Patent 6,225,460 Bischofberger	DEFS_TAF_000367	DEFS_TAF_000421
DTX-098	EP 0206459 B1 Holy and Rosenberg	TAF_MEIER000294	TAF_MEIER000304
DTX-099	WO 96/29336 McGuigan	DEFS_TAF_000466	DEFS_TAF_000537
DTX-100	WO 95/07920 Bischofberger	DEFS_TAF_000150	DEFS_TAF_000304
DTX-101	WO 00/18775 McGuigan	DEFS_TAF_001185	DEFS_TAF_001319
DTX-102	Provisional Application 60/220,021 filed July 21, 2000 (Parent to '791 patent)	GILEAD_TAF02010728	GILEAD_TAF02010780
DTX-103	Ariens, Eur. J. Clin. Pharmacol., 26:663-668 (1984)	TAF_MEIER000180	TAF_MEIER000185
DTX-104	Arimilli, Antiviral Chemistry and Chemotherapy, 8(6):557-564(1997)	DEFS_TAF_000627	DEFS_TAF_000634
DTX-105	Balzarini, Proc. Natl. Acad. Sci. USA, 86:332-36 (1989)	TAF_MEIER000186	TAF_MEIER000190
DTX-106	Balzarini et al., AIDS, 5(1):21-28 (1991)	TAF_MEIER000191	TAF_MEIER000199
DTX-107	Bazarini,Antimicrob. Agents and Chemother., 37(2) :332-338 (1993)	TAF_MEIER000173	TAF_MEIER00179
DTX-108	Balzarini et al., Molecular Pharmacology, 50:1207-1213 (1996)	TAF_MEIER000319	TAF_MEIER000325
DTX-109	Balzarini et al., Proc. Natl. Acad. Sci., 93:7295-7299 (1996)	TAF_MEIER000305	TAF_MEIER000309
DTX-110	Balzarini et al., FEBS Letters, 410:324-328 (1997)	TAF_MEIER000371	TAF_MEIER000375
DTX-111	Balzarini et al., Molecular Pharmacology, 56:1354-1361 (1999)	TAF_MEIER000092	TAF_MEIER000099
DTX-112	Balzarini et al., Molecular Pharmacology, 58(5):928-935 (2000)	DEFS_TAF_000586	DEFS_TAF_000593
DTX-113	Baraditch-Crovo, Infectious Dis., 176:406-413 (1997)	TAF_MEIER000326	TAF_MEIER000333

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-114	Bronson, ACS Symposium Series 401, Nucleotide Analogs as Antiviral Agents, 72-87 (1989)	TAF_MEIER000200	TAF_MEIER000210
DTX-115	Calio et al., Antiviral Res., 23(1):77-89 (1994)	TAF_MEIER000334	TAF_MEIER000346
DTX-116	Cave and Supakorn, "What is P Value?", Biosci (2016)	GILEAD_TAF02566585	GILEAD_TAF02566587
DTX-117	Chapman et al. Nucleoside, Nucleotides & Nucleic Acids, 1085-190 (2001) "Chapman I"	GILEAD_TAF00029389	GILEAD_TAF00029396
DTX-118	Chapman et al., Nucleosides Nucleotides Nucleic Acids, 20(4-7) 621-628 (2001) "Chapman II"	DEFS_TAF_000641; GILEAD-TAF00029397	DEFS_TAF_000650; GILEAD TAF00029406
DTX-119	Cohen, Science, 270:1121-1122 (1995)	TAF_MEIER000263	TAF_MEIER000265
DTX-120	De Clercq, Nature, 323:464-67 (1986) "De Clercq 1986"	TAF_MEIER000211	TAF_MEIER000215
DTX-121	DeClercq, Antiviral Research 8:261-272 (1987)	TAF_MEIER000266	TAF_MEIER000278
DTX-122	De Clercq, Advances in Antiviral Drug Design, 3:69-91(1999)	GILEAD_TAF02560975	GILEAD-TAF02560998
DTX-123	De Clercq, Reviews in Medical Virology 10:255-257 (2000)	GILEAD_TAF02560952	GILEAD_TAF02560974
DTX-124	Farber, Nature, 593:507-509 (2021)	GILEAD_TAF02566609	GILEAD_TAF02566612
DTX-125	FDA Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances (1987)	TAF_MEIER000216	TAF_MEIER000262
DTX-126	FDA Policy for Development of New Stereoisomeric Drugs, Chirality 4:338-340 (1992)	DEFS_TAF_000594	DEFS_TAF_000601
DTX-127	Franchetti et al., J. Med. Chem., 37:3534-3541 (1994)	DEFS_TAF_000567	DEFS_TAF_000574
DTX-128	Fridland et al., Antiviral Res., 34, A49, 27 (1997)	TAF_MEIER00347	
DTX-129	Geddes & Grossset, Family Medical Dictionary, lymphoid tissue at p. 159(2007)	GILEAD_TAF02566606	GILEAD_TAF02566608
DTX-130	Hudson and Keay, J. Chem Soc., 2463-2469 (1956)	TAF_MEIER000445	TAF_MEIER000451
DTX-131	Jones and Bischofberger, Antiviral Research, 27: 1-17 (1995)	DEFS_TAF_000432	DEFS_TAF_000448
DTX-132	Kurihara et al., Pure & Applied Chemistry, 69 (9): 2007-2025 (1997)	DEFS_TAF_000602	DEFS_TAF_000620
DTX-133	Li et al., Antiviral Research, 13:237-252 (1990)	GILEAD_TAF02563073	GILEAD_TAF02563088
DTX-134	Lee, et al., Antimicrobial Agents and Chemotherapy, 49(5):1898-1906 (May 2005)	NAT-TAF--17995	NAT-TAF-018003
DTX-135	Lee et al., Antiviral Research 71:254-259 (2006)	GILEAD_TAF02563067	GILEAD_TAF02563072
DTX-136	McGuigan et al., Antiviral Chem. And Chemo., 1(2):107-113 (1990)	NAT-TAF-018220	NAT-TAF-018226
DTX-137	McGuigan, J. Med. Chem., 36:1048-1052 (1993) "McGuigan 1993"	NAT-TAF-017684	NAT-TAF-017688
DTX-138	MCGuigan et a., FEBS Letters 351:11-14 (1994)	TAF_MEIER000354	TAF_MEIER000357
DTX-139	McGuigan et al., Antiviral Chem. & Chemo., 7(4):184-188 (1996) "McGuigan 1996"	DEFS_TAF_000538	DEFS_TAF_000542
DTX-140	McGuigan et al., Antiviral Chem. Chemoth. 7:31-36 (1996)	TAF_MEIER000348	TAF_MEIER000353

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-141	McGuigan et al., J. Med. Chem.,39:1748-1753 (1996)	TAF_MEIER000358	TAF_MEIER000363
DTX-142	McGuigan et al., Antiviral Research, 35:195-204 (1997) "McGuigan 1997"	DEFS_TAF_000543	DEFS_TAF_000552
DTX-143	McGuigan et al., Antiviral Chem. And Chemo.,9:473-479 (1998) "McGuigan 1998"	DEFS_TAF_000553	DEFS_TAF000559
DTX-144	McGuigan et al., Bioorganic & Medicinal Chem. Letters 10:645-647 (2000)n"McGuigan 2000"	GILEAD_TAF02563089	GILEAD_TAF02563091
DTX-145	Meier et al. SynLett, 233-242 (1998) "Meier I"	DEFS_TAF_000422	DEFS_TAF_000431
DTX-146	Meier et al., J. Med. Chem., 41:1417-1427 (1998) "Meier II"	DEFS_TAF_000575	DEFS_TAF_000585
DTX-147	Mehellou et al., Organic & Biomolecular Chemistry,7:2548-2553 (2009)	TAF_BLAIR000163	TAF_BLAIR000169
DTX-148	Murakami, et al., Antimicrobial Agents and Chemotherapy, 59 (6) 3563-3569 (2015)	TAF_BLAIR000234	TAF_BLAIR000240
DTX-149	Naesens et al., Antimicrobial Agents and Chemotherapy, 42(7):1568-1573 (1998)	DEFS_TAF_000635	DEFS_TAF_000640
DTX-150	Pauwels, Antimicrobial Agents and Chemotherapy, 32(7):1025-30 (1988)	TAF_MEIER000164	TAF_MEIER000169
DTX-151	Saboulard, Molecular Pharmacology, 56:693-704 (1999)	DEFS_TAF_000449	DEFS_TAF_000460
DTX-152	Shaw, Pharmaceutical Research, 14(12):1824-1829 (1997)	DEFS_TAF_000621; GILEAD_TAF00165694	DEFS_TAF_000626; GILEAD_TAF00165699
DTX-153	Srinivas, Antimicrobial Agents and Chemotherapy, 37(1): 2247-2250 (1993)	TAF_MEIER000284	TAF_MEIER000287
DTX-154	Tsai, Science, 270:1197-99 (1995)	TAF_MEIER000279	TAF_MEIER000283
DTX-155	Westheimer et al., JACS, 110:181-185 (1998)	TAF_MEIER000452	TAF_MEIER000456
DTX-156	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21	TAF_Meier000481	TAF_MEIER000547
DTX-157	CV of Ian A. Blair, Ph.D.		
DTX-158	Tables 1 and 2 excretion and tissue distribution of C-14	GILEAD_TAF00073040	GILEAD_TAF00073042
DTX-159	Blair Plots No. 1 - non-lymph v lymph GS4331 and GS7340 (3 boxes)		
DTX-160	Blair Plots No. 2 - non-lymph v lymph tissues GS-7097 and GS7340 (2 boxes)		
DTX-161	Blair Plots No. 3- Non-lympoid v. 6-lymphoid GS-4331 and GS-7340 (2 boxes)		
DTX-162	Blair Plots No.4 - Non-lympoid v. 6-lymphoid GS4331, GS-7097 and GS-7340 (3 boxes)		
DTX-163	Blair Plots No. 5 - Non-lympoid v. 6-lymphoid TD and GS-7340 (2 boxes)		
DTX-164	Blair Plots No. 6 - Non-lympoid v. 9-lymphoid GS-4331 ad GS-7340 (2 boxes)		

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-165	Blair Plots No. 7 - Non-lymphoid v. 9-lymphoid GS4331, GS-7097 and GS-7340 (3 boxes)		
DTX-166	Blair Plots No. 8 - Non-lymphoid v. 9-lymphoid TD and GS-7340 (2 boxes)		
DTX-167	Blair Plots No. 9 - Non-lymphoid v. 6-lymphoid ratio 7340/7097 and 7340/TD (2 boxes)		
DTX-168	Blair Plots No.10 - Non-lymphoid v. 9-lymphoid ratio 7340/7097 and GS-7340/TD (2 boxes)		
DTX-169	Birkus, et al., Molecular Pharmacology, 74(1):92-100(2008)	DEFS-TAF-000716	DEFS-TAF-000724
DTX-170	Ray et al., Antiviral Research, 125:63-70 (2016)	GILEAD_TAF00211978	GILEAD_TAF00211985
DTX-171	Babusis, et al., Molecular Pharmaceutics, 10:459-466 (2013)	GILEAD_REGTAF00024312	GILEAD_REGTAF00024319
DTX-172	Callebaut, et al., Antimicrobial Agents and Chemotherapy, 59(10):5909-5916 (2015)	GILEAD_TAF00807098	GILEAD_TAF00807105
DTX-173	Krise, et al., Advanced Drug Delivery Reviews, 19:287-310 (1996)	GILEAD_TAF02566309	GILEAD_TAF02566332
DTX-174	Chapman draft article dated March 1, 2000	GILEAD_TAF00075966	GILEAD_TAF00075967
DTX-175	Interoffice memo from Eisenberg dated January 14, 1998, re summary	GILEAD-TAF00723138	GILEAD_TAF00723144
DTX-176	Interofice memo from He dated June 2, 1999, re supplement to minutes	GILEAD_TAF00059842	GILEAD_TAF00059847
DTX-177	Interoffice memo from Sparacino dated August 3, 1999, re recommended GS-7340 in-process acceptance limits	GILEAD_TAF00781022	GILEAD_TAF00781023
DTX-178	PMPA-Monoamide HPLC Methods Development Goals	GILEAD_TAF00781020	GILEAD_TAF00781021
DTX-179	Kernan memo to Sparacinore GS-7340 HPLC Methods	GILEAD_TAF01571465	GILEAD_TAF01571466
DTX-180	Chapman powerpoint presentation "Practical Synthesis, Separation and Stereochemical assignment of the PMPA Prodrug GS-7340	GILEAD_TAF00787195	GILEAD_TAF00787214
DTX-181	Chapman notes re group meeting September 29, 2000	GILEAD_TAF00076140	GILEAD_TAF00076141
DTX-182	Excerpts from Lab Notebook 1603 issued to Chapman	GILEAD_TAF01702599	GILEAD_TAF01702692
DTX-183	Chapman notes re GS-7340 Status dated August 29, 2000	GILEAD_TAF00777929	
DTX-184	Chapman Research Report July 2000 - August 2001	GILEAD_TAF00076176	GILEAD_TAF00076188
DTX-185	Rudy Ng Research Report October 2001 to October 2002	GILEAD_TAF00725791	GILEAD_TAF00725806
DTX-186	Powerpoint PMPA Prodrug Back-Up	GILEAD_TAF00072971	GILEAD_TAF00072988
DTX-187	Lee and He memo dated October 21, 1999, re back-up candidate for Tenofovir DF	GILEAD_TAF00776335	GILEAD_TAF00776341
DTX-188	Eisenberg memo dated December 7, 1999, re summary	GILEAD_TAF00721327	GILEAD_TAF00721331
DTX-189	Lee memo dated February 7, 2000, re GS-7340-2 IND Selection	GILEAD_TAF00073465	GILEAD_TAF00073471
DTX-190	Eisenberg memo dated March 13, 2000,re distribution and metabolism of radiolabelled GS-7340	GILEAD_TAF00721279	GILEAD_TAF00721283

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-191	Draft study report D990173-BP dated April 24 2000	GILEAD_TAF00722149	GILEAD_TAF00722172
DTX-192	Ennis meeting summary dated June 2, 2000, re tenofovir amide prodrug team meeting	GILEAD-TAF00211775	GILEAD_TAF00211777
DTX-193	Lee interoffice memo dated June 23, 2000, re PMPA Amide Prodrug GS-7340 Rational for Development	GILEAD_TAF00721606	GILEAD_TAF00721606.0018
DTX-194	Nucleotide Round Table September 12, 2020	GILEAD_TAF00234988	GILEAD_TAF00234992
DTX-195	Lee Powerpoint "In Vivo Targeting to the Lymphatic System after Oral Administration of an Amide Prodrug of Tenofovir (PMPA)	GILEAD_TAF00776758	GILEAD_TAF00776777
DTX-196	Eisenberg et al., Nucleosides Nucleotides & Nucleic Acids, 20(4-7):1091-1098 (2001)	NAT-TAF-017986	NAT-TAF-017994
DTX-197	Virsik memo to develop committee re financial analysis of GS7340 as a Tenofovir Exclusivity Extension dated September 18, 2003	GILEAD_TAF02268406	GILEAD_TAF02268413
DTX-198	Critical Activity Status Report September 2004	GILEAD_TAF02010615	GILEAD_TAF02010685
DTX-199	Memorandum Order DI 236 on Claim Construction, May 26, 2021		
DTX-200	Plaintiff's Response to Defendants' Joint Interrogatory No. 1 dated January 19, 2021		
DTX-201	Gilead's Reponses to Defendants Joint Set of Interrogatories (2-8) dated June 15, 2021		
DTX-202	Gilead Supplemental Reponses to Defendants Joint Interrogatory 1 dated September 16, 2021		
DTX-203	Defendant's Notice of Deposition of Richard Hung Chiu Yu		
DTX-204	Curriculum Vitae of Richard Hung Chiu Yu		
DTX-205	U.S. Patent No. 9,296,769	GILEAD_TAF00006985	GILEAD_TAF00006997
DTX-206	E-mail with research reports	GILEAD_TAF00491481	GILEAD_TAF00491487
DTX-207	Laboratory Notebook No. 1309	GILEAD_TAF00779891	GILEAD_TAF00779960
DTX-208	Laboratory Notebook No. 1509	GILEAD_TAF01704350	GILEAD_TAF01704461
DTX-209	Gilead Production Document, Custodian Mark Sparacino	GILEAD_TAF00781408	
DTX-210	Laboratory Notebook No. 1504	GILEAD_TAF01702462	GILEAD_TAF01702470
DTX-211	Laboratory Notebook No. 1864	GILEAD_TAF01666759	GILEAD_TAF01666955
DTX-212	Batch Production Record, Harlan Chapman	GILEAD_TAF01428356	GILEAD_TAF01428426
DTX-213	Gilead Production Document dated Sept. 6, 2002	GILEAD_TAF0077840	GILEAD_TAF00778541
DTX-214	Preformulation Report dated Aug. 4, 2000	GILEAD_TAF00776692	GILEAD_TAF00776718
DTX-215	Gilead Sciences, Inc. GS-7340-02 Tablets, Section 7, Chemistry, Manufacturing, and Controls	GILEAD_REGTAF00155558	GILEAD_REGTAF00155751
DTX-216	Email from R. Yu to J. Wang, Apr. 15, 2015	GILEAD_TAF00367106	GILEAD_TAF00367107
DTX-217	Analytical Chemistry Report	GILEAD_TAF00367108	GILEAD_TAF00367193

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-218	E-mail from S. Wang, Apr. 23, 2002	GILEAD_TAF00769035	
DTX-219	Email from R. Yu to A. Chiu and attachments	GILEAD_TAF00275772	GILEAD_TAF00275881
DTX-220	Interoffice Memorandum from Bill Lee, dated June 23, 2000, with attachments	GILEAD_TAF00758658	GILEAD_TAF00758658-0018
DTX-221	PDM Review dated Aug. 3, 2010	GILEAD_TAF02245773	GILEAD_TAF02245823
DTX-222	GS-7340-02 Monthly Report for Oct. 2010	GILEAD_TAF00669211	GILEAD_TAF00669211-0024
DTX-223	Laboratory Notebook No. 4433	GILEAD_TAF01661679	GILEAD_TAF01661875
DTX-224	Yu Declaration	GILEAD_TAF00729509	GILEAD_TAF00729518
DTX-225	Development Plan, Project: GS-7340	GILEAD_TAF02011939	GILEAD_TAF02011969
DTX-226	U.S. Patent No. 7,390,791	DEFS-TAF-000651	DEFS-TAF-000678
DTX-227	U.S. Patent No. 7,803,788	DEFS-TAF-000679	DEFS-TAF-000707
DTX-228	The Viread Label	DEFS-TAF-000750	DEFS-TAF-000793
DTX-229	The Truvada Label	DEFS-TAF-000794	DEFS-TAF-000826
DTX-230	WO 2008/143500	DEFS-TAF-000827	DEFS-TAF-000877
DTX-231	US Patent No. 8,049,009 and US Pre-Grant Publication No. 2009/0286981	DEFS-TAF-000878 DEFS-TAF-000892	DEFS-TAF-000891 DEFS-TAF-000906
DTX-232	FDA Guidance for Industry ANDAS: Impurities in Drug Substances, November 1999	DEFS-TAF-000907	DEFS-TAF-000925
DTX-233	Lee et al., "Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue," Antimicrobial Agents and Chemotherapy, May 2005 Vol. 49 No. 5 pp. 1898-1906	DEFS-TAF-000926	DEFS-TAF-000934
DTX-234	Yadav, A.V. et al., "Co-Crystals: A Novel Approach to Modify Physicochemical Properties of Active Pharmaceutical Ingredients," 71(4) Ind. J. Pharm Sci. 359, 359-60 (2009)	DEFS-TAF-000935	DEFS-TAF-000951
DTX-235	Dova, E. et al., U.S. Patent Publication No. 2009/0176983, "Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal," published July 9, 2009	DEFS-TAF-000952	DEFS-TAF-000979
DTX-236	Lee et al., "Characterization and Anisotropic Lattice Expansion/Contraction of Polymorphs of Tenofovir Disoproxil Fumarate," 10 Crys. Growth & Des. 2314-22 (2010)	DEFS-TAF-000980	DEFS-TAF-000988
DTX-237	Cihlar, Thomas, "Amidate Prodrugs of Nucleoside Phosphonates: from Design to in vivo Proof of Concept," 10 Collection Symposium Series 45, 46 (2008)	DEFS-TAF-000989	DEFS-TAF-000997
DTX-238	EMEA Scientific Discussion for the Approval of Viread (2005)	DEFS-TAF-000998	DEFS-TAF-001040
DTX-239	Byrn et al., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, Pharm. Res., 12(7): 945-954 (1995)	APO-TEN-Stephenson 000001	APO-TEN-Stephenson 000010

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-240	Miller, et al., "Identifying the Stable Polymorph Early in the Drug Discovery – Development Process," Pharm. Dev. Tech., 10:291–297 (2005)	APO-TEN-Stephenson 000011	APO-TEN-Stephenson 000017
DTX-241	Gu, et al., Polymorph Screening: Influence of Solvents on the Rate of Solvent-Mediated Polymorphic Transformation, Journal of Pharmaceutical Sciences, 90:1878-1890 (2001)	APO-TEN-Stephenson 000018	APO-TEN-Stephenson 000030
DTX-242	"Guidelines for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances, February 1987	APO-TEN-Stephenson 000113	APO-TEN-Stephenson 000160
DTX-243	Bastin et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," Org. Process Res. Dev., 4:427-435 (2000)	DEFS-TAF-001078	DEFS-TAF-001086
DTX-244	Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., 66:1-19 (1977)	DEFS-TAF-001087	DEFS-TAF-001105
DTX-245	Gould, "Salt Selection for Basic Drugs," Intl J. Pharm., 33:201-217 (1986)	DEFS-TAF-001168	DEFS-TAF-001184
DTX-246	"Crystallization," ed. by J.W. Mullin (2001)	APO-TEN-Stephenson 000031	APO-TEN-Stephenson 000035
DTX-247	Handbook of Pharmaceutical Salts, Selection, and Use, Editors P.H. Stahl, C.G. Wermuth, Chapter 7, "A Procedure for Salt Selection and Optimization," Eds. 2002, ISBN 3-906390-26-8	APO-TEN-Stephenson 000036	APO-TEN-Stephenson 000066
DTX-248	Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances," Federal Register, Vol. 65, No. 251, pp. 83041-83063 (December 29, 2000)	APO-TEN-Stephenson 000067	APO-TEN-Stephenson 000112
DTX-249	Delaney et al., "Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus," Antimicrob. Agents Chemother., 50(7), 2471-2477 (2006)	DEFS-TAF-001106	DEFS-TAF-001112
DTX-250	Gallant J.E. and Deresinski S., Tenofovir Disoproxil Fumarate, Clin. Infect. Dis., 37(1), 944-950 (2003)	DEFS-TAF-001161	DEFS-TAF-001167
DTX-251	Bernstein, J., Polymorphism in Molecular Solids, 410, Oxford University Press (2002)	APO-TEN-Stephenson 000161	APO-TEN-Stephenson 000197
DTX-252	Carlson et al., An integrated high throughput workflow for pre-formulations: Polymorph and salt selection studies, Drug Development, 10-15 (July/August 2003)	APO-TEN-Stephenson 000198	APO-TEN-Stephenson 000204
DTX-253	Chemburkar, et al., Dealing with the Impact of Ritonavir Polymorphs on the Late Staged of Bulk Drug Process Development, Organic Process Research Development, 4:413-417 (2002)	APO-TEN-Stephenson 000205	APO-TEN-Stephenson 000209

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-254	Desrosiers, P.J., "The Potential of Preformulation," <i>Modern Drug Discovery</i> , 7, 40–43 (2004)	APO-TEN-Stephenson 000211	APO-TEN-Stephenson 000214
DTX-255	Desrosiers, P.J., High-Throughput Screening Techniques for Preformulation: Salt Selection and Polymorph Studies, <i>Acta Crystallographica, A58 (supplement)</i> (2002)	APO-TEN-Stephenson 000210	
DTX-256	Grant, David J.W., Theory and Origin of Polymorphism, Polymorphism in <i>Pharma Solids</i> , Chapter 1, 1-12 (1999)	APO-TEN-Stephenson 000215	APO-TEN-Stephenson 000247
DTX-257	Guillory, J. Keith, Generation of Polymorphs, Hydrates, Solvates and Amorphous Solids, Polymorphism in Pharmaceutical Solids, Chapter 5, 183-226 (1999)	APO-TEN-Stephenson 000248	APO-TEN-Stephenson 000295
DTX-258	Haleblin, J. et al., Pharmaceutical Applications of Polymorphism, <i>Journal of Pharmaceutical Sciences</i> , 58:911-929 (1969)	APO-TEN-Stephenson 000296	APO-TEN-Stephenson 000314
DTX-259	Hilfiker et al., "Polymorphism – Integrated Approach from High-Throughput Screening to Crystallization Optimization," <i>Journal of Thermal Analysis and Calorimetry</i> , 73:429-440 (2003)	APO-TEN-Stephenson 000332	APO-TEN-Stephenson 000343
DTX-260	ICH Harmonised Tripartite Guideline Impurities: Guideline For Residual Solvents Q3C(R5), current Step 4 version dated 4 February 2011 <i>Parent Guideline dated 17 July 1997</i>	APO-TEN-Stephenson 000344	APO-TEN-Stephenson 000372
DTX-261	ICH Harmonised Tripartite Guideline, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Q6A (October 6, 1999)	APO-TEN-Stephenson 000373	APO-TEN-Stephenson 000407
DTX-262	IN201621044186A	APO-TEN-Stephenson 000419	APO-TEN-Stephenson 000429
DTX-263	IN201641044268A	APO-TEN-Stephenson 000408	APO-TEN-Stephenson 000418
DTX-264	Kresimir, et al., Disappearing Polymorphs Revisited, <i>Angewandte Chemie, International Edition</i> , 54(24):6972-6993 (2015)	APO-TEN-Stephenson 000430	APO-TEN-Stephenson 000451
DTX-265	Morissette et al., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, <i>Advanced Drug Delivery Reviews</i> , 56(3):275-300 (2004)	APO-TEN-Stephenson 000452	APO-TEN-Stephenson 000477
DTX-266	Nangia, Ashwiniw and Guatam R. Desiraju, Pseudopolymorphism: Occurrences of Hydrogen Bonding Organic Solvents in Molecular Crystals, <i>Chemical Communications</i> , 7:605-606 (1999)	APO-TEN-Stephenson 000478	APO-TEN-Stephenson 000479
DTX-267	Stahl Wermuth Handbook of Pharmaceuticals Salts Properties Selection and Use 2002 Ch-11- page 233 & 249-263	APO-TEN-Stephenson 000315	APO-TEN-Stephenson 000331

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-268	van Langevelde, Arjen and Erwin Blomsma, High-throughput screening in solid form selection, <i>Acta Crystallographica</i> , A58 (supplement), (2002)	APO-TEN-Stephenson 000480	
DTX-269	Vippahuinta, et al., Crystalline Solids, <i>Advanced Drug Delivery Reviews</i> , 48:3-26 (2001)	APO-TEN-Stephenson 000481	APO-TEN-Stephenson 000504
DTX-270	Ahlneck, C., et al., "The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state," <i>International Journal of Pharmaceutics</i> , 62 (1990) 87-95	APO-TEN-Stephenson 000505	APO-TEN-Stephenson 000513
DTX-271	Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World, https://www.gilead.com/news-and-press/press-room/press-releases/2014/7/gilead-announces-new-agreement-with-medicines-patent-pool-for-access-to-medicines-in-developing-world-countries	APO-TEN-Stephenson 000535	APO-TEN-Stephenson 000536
DTX-272	Gilead Offers Voluntary Licenses for Manufacturing of Viread in Developing World, https://www.gilead.com/news-and-press/press-room/press-releases/2006/5/gilead-offers-voluntary-licenses-for-manufacturing-of-viread-in-developing-world	APO-TEN-Stephenson 000537	
DTX-273	Guerrieri, P., et al., "Effect of Small Levels of Impurities on the Water Vapor Sorption Behavior of Ranitidine HCl," <i>Pharm. Res.</i> 2007, 24, 147-156	APO-TEN-Stephenson 000538	APO-TEN-Stephenson 000547
DTX-274	Guerrieri, P.P., et al., "Phase Behavior of Ranitidine HCl in the Presence of Degradants and Atmospheric Moisture-Impact on Chemical Stability," <i>Langmuir</i> (2008), 24(8), 3850-3856	APO-TEN-Stephenson 000548	APO-TEN-Stephenson 000554
DTX-275	FDA Guidance for Industry, Q3A Impurities in New Drug Substances, June 2008	APO-TEN-Stephenson 000566	APO-TEN-Stephenson 000582
DTX-276	Henck, J.-O. and Byrn, S.R. "Designing a molecular delivery system within a preclinical timeframe," <i>Drug Discovery Today Volume 12, Numbers 5/6 March 2007 pp189-199</i>	APO-TEN-Stephenson 000555	APO-TEN-Stephenson 000565
DTX-277	ICH Harmonised Tripartite Guideline, Impurities In New Drug Products, Q3B(R2), June 2006	APO-TEN-Stephenson 000583	APO-TEN-Stephenson 000598
DTX-278	Saifee, M., et al., "Drug Polymorphism: A Review International Journal of Health Research," December 2009; 2(4): 291-306; at abstract	APO-TEN-Stephenson 000599	APO-TEN-Stephenson 000616

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-279	Salecki-Gerhardt, A., et al., "Assessment of disorder in crystalline solids," International Journal of Pharmaceutics, 101 (1994) 237-247	APO-TEN-Stephenson 000524	APO-TEN-Stephenson 000534
DTX-280	Singhal, D., et al., "Drug polymorphism and Dosage Form Design: A Practical Perspective," Advanced Drug Delivery Reviews 56 (2004) 335-347	APO-TEN-Stephenson 000618	APO-TEN-Stephenson 000629
DTX-281	Ueda, et al., "Control of Polymorphs and Crystal Habit in Crystallization of N2-(1(S)-Ethoxycarbonyl-3-Phenylpropyl)-N6-Trifluoroacetyl-L-Lysine," Chem. Eng. Res. And Design, 85(A3) 406-409, at 406 (2007)	APO-TEN-Stephenson 000630	APO-TEN-Stephenson 000633
DTX-282	US622546081	APO-TEN-Stephenson 000634	APO-TEN-Stephenson 000688
DTX-283	Wang, Y. et al., "Enantioenrichment by Crystallization. Organic Process Research & Development," (2008), 12(2), Wang, Y. et al., "Enantioenrichment by Crystallization. Organic Process Research & Development," (2008), 12(2), 282-290	APO-TEN-Stephenson 000689	APO-TEN-Stephenson 000697
DTX-284	Zhang, et al., "Phase Transformation Considerations During Process Development and Manufacture of Solid Oral Dosage Forms," Advanced Drug Delivery Reviews 56 (2004) 371-390	APO-TEN-Stephenson 000699	APO-TEN-Stephenson 000717
DTX-285	Gilead lab notebook 4433	GILEAD_TAF01661741	GILEAD_TAF01661845
DTX-286	Gilead internal document	GILEAD_TAF00233334	
DTX-287	Gilead internal document	GILEAD_TAF00228298	GILEAD_TAF002282304
DTX-288	Gilead internal document	GILEAD_TAF02010609	
DTX-289	US Patent No. 6,225,460	DEFS-TAF-000367	DEFS-TAF-000421
DTX-290	Memorandum Order DI 236 on Claim Construction, May 26, 2021		
DTX-291	Plaintiff's Response to Defendants' Joint Interrogatory No. 1 dated January 19, 2021		
DTX-292	Gilead's Responses to Defendants Joint Set of Interrogatories (2-8) dated June 15, 2021		
DTX-293	Gilead Supplemental Responses to Defendants Joint Interrogatory 1 dated September 15, 2021		
DTX-294	Plaintiff Gilead Sciences, Inc. Complaint for Patent Infringement Dated February 7, 2020		
DTX-295	Plaintiff Gilead Sciences, Inc.'s First Amended Complaint for Patent Infringement, dated November 23, 2020		
DTX-296	Stipulation and [Proposed] Order of Infringement Concerning Defendants Hetero USA Inc., Hetero Labs Limited Unit-V, and Hetero Labs Limited, dated April 7, 2021		

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-297	Memorandum Order, dated May 26, 2021		
DTX-298	Stipulation and [Proposed] Order of Infringement Concerning Defendant Cipla Limited and of the Authenticity and Admissibility of Certain Documents, dated September 20, 2021		
DTX-299	Stipulation and [Proposed] Order of Infringement Concerning Defendant Laurus Labs Limited and of the Authenticity and Admissibility of Certain Documents, dated September 20, 2021		
DTX-300	Stipulation and [Proposed] Order of Infringement Concerning Defendant Natco Pharma Limited and of the Authenticity and Admissibility of Certain Documents, dated September 20, 2021		
DTX-301	Plaintiff Gilead Sciences, Inc.'s Second Amended Complaint for Patent Infringement, dated October 15, 2021 Consent Judgment and Order, dated November 23, 2021		
DTX-302	Stipulation and [Proposed] Order of Infringement Concerning Defendant Apotex, Inc., dated November 24, 2021		
DTX-303	Stipulation and [Proposed] Order of Infringement Concerning Defendant Lupin Limited, dated December 1, 2021		
DTX-304	Stipulation and Order, dated January 12, 2022		
DTX-305	Consent Judgment and Order, dated January 25, 2022		
DTX-306	NOT USED		
DTX-307	NOT USED		
DTX-308	NOT USED		
DTX-309	NOT USED		
DTX-310	NOT USED		
DTX-311	NOT USED		
DTX-312	Expert Report of Dr. Chloe Lynne Thio, M.D., dated January 14, 2022		
DTX-313	Expert Report of Gregory Stephenson, Ph.D. Regarding Invalidity of U.S. Patent Nos. 8,754,065, and 9,296,769, dated January 18, 2022		
DTX-314	Supplemental Opening Expert Report of Chris Meier, Ph.D., dated January 20, 2022		
DTX-315	Expert Report and Disclosure of Julie L. Davis, dated March 25, 2022		
DTX-316	Rebuttal Expert Report of Jeffrey Krise, Ph.D., dated March 25, 2022		

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-317	Rebuttal Expert Report of David Piontowsky, M.D., dated March 25, 2022		
DTX-318	Rebuttal Expert Report of Bernhardt L. Trout, Ph.D., dated March 25, 2022		
DTX-319	Reply Expert Report of Gregory Stephenson, Ph.D., dated April 22, 2022		
DTX-320	Reply Expert Report of Chris Meier, Ph.D., dated April 22, 2022		
DTX-321	Gilead Pharmaceutical Development Report (Apr. 3, 2015)	GILEAD_REGTAF00026644	GILEAD_REGTAF00026665
DTX-322	Gilead Reimbursement Toolkit	GILEAD_REGTAF00056782	GILEAD_REGTAF00056803
DTX-323	TAF Market Potential US QualQuant Presentation (Mar. 2013)	GILEAD_TAF00034736	GILEAD_TAF00034802
DTX-324	2017 EMAAC and NM Opening	GILEAD_TAF00210546	GILEAD_TAF00210698
DTX-325	190423 HIV Market Therapy Evolution	GILEAD_TAF00224054	GILEAD_TAF00224077
DTX-326	VEM Maximization - DPT update 2.19.20	GILEAD_TAF00225035	GILEAD_TAF00225070
DTX-327	Scientific Advisory Board Report of Meetings held on July 29 and 30, 2003 at Gilead Sciences, Foster City, CA	GILEAD_TAF00228298	GILEAD_TAF00228304
DTX-328	FW: API Cost	GILEAD_TAF00233334	GILEAD_TAF00233334
DTX-329	GS7340 Base Case Forecast Assumptions	GILEAD_TAF00236764	GILEAD_TAF00236764
DTX-330	GS7340 Base Case Forecast Assumptions	GILEAD_TAF00236765	GILEAD_TAF00236765
DTX-331	RE: Gilead Daily Analyst Reports and Information Packet 05.13.10	GILEAD_TAF00237428	GILEAD_TAF00237431
DTX-332	2017 HIV FPOA Exec Summary 9.14.16_preread for Medical Affairs	GILEAD_TAF00379090	GILEAD_TAF00379150
DTX-333	RA Ad Promo 2017 Mid-Year Overview FINAL18JUL17	GILEAD_TAF00463727	GILEAD_TAF00463730
DTX-334	UBS_Biotech TAF survey slides 5_17_13_SA approved	GILEAD_TAF00564455	GILEAD_TAF00564491
DTX-335	Amidate Dev Comm Mtg	GILEAD_TAF00721606	GILEAD_TAF00721623
DTX-336	GS-7340 Strategy Summary	GILEAD_TAF00728954	GILEAD_TAF00728954
DTX-337	02-Koomey Bridges CEO HIV Day Commercial Presentation FINAL	GILEAD_TAF00737303	GILEAD_TAF00737349
DTX-338	GS-7340 Business Review	GILEAD_TAF00762050	GILEAD_TAF00762050
DTX-339	Gs 7340 review FINAL	GILEAD_TAF00762051	GILEAD_TAF00762065
DTX-340	North America Executive Summary_2017 HIV POA midyear	GILEAD_TAF01605044	GILEAD_TAF01605100
DTX-341	PTFM0086_HIV Market Landscape Presentation (All Treatment)_V1	GILEAD_TAF01629987	GILEAD_TAF01629994
DTX-342	190610 HIV Market Therapy Evolution	GILEAD_TAF01639311	GILEAD_TAF01639339
DTX-343	Form 10-K, 2017-02-27	GILEAD_TAF01673498	GILEAD_TAF01673623
DTX-344	Form 10-K, 2018-02-27	GILEAD_TAF01673625	GILEAD_TAF01673748
DTX-345	Form 10-K, 2019-02-26	GILEAD_TAF01673750	GILEAD_TAF01673993
DTX-346	Form 10-K/A, 2019-04-18 Amendment	GILEAD_TAF01673995	GILEAD_TAF01674404

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-347	GS-7340 Preliminary Commercial Recommendation, Aug. 19, 2002	GILEAD_TAF01674683	GILEAD_TAF01674690
DTX-348	US Price Increase Assumptions	GILEAD_TAF01685857	GILEAD_TAF01685857
DTX-349	2017 Price Recommendation 12_18_16	GILEAD_TAF01685860	GILEAD_TAF01685880
DTX-350	HIV Landscape Assessment Physician & Patient Apr 2016	GILEAD_TAF01687930	GILEAD_TAF01687972
DTX-351	2019 MidYear_US HIV POA_16JUL19_for Presentation	GILEAD_TAF01783547	GILEAD_TAF01783654
DTX-352	Earnings Slides Q1 2019	GILEAD_TAF01784169	GILEAD_TAF01784230
DTX-353	Microsoft_Excel_Worksheet6	GILEAD_TAF01787406	GILEAD_TAF01787406
DTX-354	IMS Weekly Summary – 2016.07.08	GILEAD_TAF01787774	GILEAD_TAF01787774
DTX-355	RE: Market Maps - could you please send digital file?	GILEAD_TAF01800544	GILEAD_TAF01800544
DTX-356	Prescription Data for HIV, HBV, Oral BCR products and Ranexa for the week-ending 12/09/16 - IMS data	GILEAD_TAF01800633	GILEAD_TAF01800635
DTX-357	RE: FSS Pricing Recommendation	GILEAD_TAF01801773	GILEAD_TAF01801776
DTX-358	HIV Portfolio BIG4 OGA 2017 Recommended Pricing	GILEAD_TAF01801777	GILEAD_TAF01801777
DTX-359	HCP HIV Treatment ATU Full Report 4Q16	GILEAD_TAF01829783	GILEAD_TAF01829866
DTX-360	04 - HIV Sep LE R1	GILEAD_TAF01830545	GILEAD_TAF01830545
DTX-361	North America HBV Executive Summary	GILEAD_TAF01834647	GILEAD_TAF01834751
DTX-362	US HIV_Draft Sep LE_vCurrent 09232019MK	GILEAD_TAF01982532	GILEAD_TAF01982599
DTX-363	HIV BU Breakfast 6-23-17	GILEAD_TAF01984618	GILEAD_TAF01984645
DTX-364	HIV BU Overview for LH 9-25-18 FINAL2	GILEAD_TAF01985815	GILEAD_TAF01985847
DTX-365	HIV Franchise Buy-Ups FINAL to LH	GILEAD_TAF01986000	GILEAD_TAF01986045
DTX-366	Gilead Corporate_Presentation Kaiser EE 29Aug2019 v4MK	GILEAD_TAF01986558	GILEAD_TAF01986613
DTX-367	2003 Memo	GILEAD_TAF02010607	GILEAD_TAF02010614
DTX-368	GS-7340 Critical Activity Status Report, Sept. 2004	GILEAD_TAF02010615	GILEAD_TAF02010635
DTX-369	FW: 2004-03-01 GS-7340 for HIV Strategy	GILEAD_TAF02012379	GILEAD_TAF02012379
DTX-370	2004-03-01 GS-7340 for HIV Strategy	GILEAD_TAF02012380	GILEAD_TAF02012390
DTX-371	HIV Franchis Strategy Updated Document	GILEAD_TAF02012402	GILEAD_TAF02012402
DTX-372	DRAFT HIV Bus. Review memo v.1. 3.5.04 DJ3_PV	GILEAD_TAF02012403	GILEAD_TAF02012412
DTX-373	TAF HBV Global Branding Guidelines_June 2016	GILEAD_TAF02132388	GILEAD_TAF02132450
DTX-374	FTAF Portfolio Overview - Finance presentation 7.9.15 (w back up)	GILEAD_TAF02154106	GILEAD_TAF02154136
DTX-375	TAF_HBV_Launch_Update_DJ_Final	GILEAD_TAF02159644	GILEAD_TAF02159675
DTX-376	[Minutes] Vemlidy Viread DPT 20May2020	GILEAD_TAF02269420	GILEAD_TAF02269423
DTX-377	2018 June LE NA Review_v 5-25 Pre-read	GILEAD_TAF02270236	GILEAD_TAF02270424
DTX-378	HIV Community_8-4-15 DP	GILEAD_TAF02330670	GILEAD_TAF02330693
DTX-379	2015 T1 POA Progress Summary	GILEAD_TAF02424239	GILEAD_TAF02424344
DTX-380	042021_Draft_HIV MS Gilead APL Study v1.0	GILEAD_TAF02551842	GILEAD_TAF02551914
DTX-381	2013-12-31 Form 10-K	GILEAD_TAF02561502	GILEAD_TAF02561661
DTX-382	2015-12-31 Form 10-K	GILEAD_TAF02561662	GILEAD_TAF02561789

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-383	2017 First Generic Drug Approvals _ FDA	GILEAD_TAF02561790	GILEAD_TAF02561800
DTX-384	2019-12-31 Form 10-K	GILEAD_TAF02561801	GILEAD_TAF02561932
DTX-385	2020 First Generic Drug Approvals _ FDA	GILEAD_TAF02561933	GILEAD_TAF02561942
DTX-386	2020-12-31 Form 10-K	GILEAD_TAF02561943	GILEAD_TAF02562062
DTX-387	2021 First Generic Drug Approvals _ FDA	GILEAD_TAF02562063	GILEAD_TAF02562077
DTX-388	2021-12-31 Form 10-K	GILEAD_TAF02562078	GILEAD_TAF02562190
DTX-389	7_New_Blockbuster_Drugs_to_Watch_in_2016	GILEAD_TAF02562191	GILEAD_TAF02562193
DTX-390	About Apotex	GILEAD_TAF02562194	GILEAD_TAF02562194
DTX-391	ANDA Approval Reports _ First-Time Generic Drug Approvals - November 2011	GILEAD_TAF02562195	GILEAD_TAF02562195
DTX-392	Beall_jmcp.2019.25.2.218	GILEAD_TAF02562196	GILEAD_TAF02562202
DTX-393	Branded Generics at Hetero - Hetero Pharma	GILEAD_TAF02562203	GILEAD_TAF02562204
DTX-394	Cipla Generics _ Cipla.pdf	GILEAD_TAF02562205	GILEAD_TAF02562209
DTX-395	Cost Considerations and Antiretroviral Therapy _ NIH	GILEAD_TAF02562210	GILEAD_TAF02562224
DTX-396	EPIVIR-PI-PIL	GILEAD_TAF02562225	GILEAD_TAF02562258
DTX-397	FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic _ FDA	GILEAD_TAF02562259	GILEAD_TAF02562260
DTX-398	FDA-Approves-Mercks-DELSTRIGO-doravirine--lamivudine--tenofovir-disoproxil-fumarate	GILEAD_TAF02562261	GILEAD_TAF02562268
DTX-399	HEC Pharm	GILEAD_TAF02562269	GILEAD_TAF02562272
DTX-400	HIV Basics _ HIV_AIDS _ CDC	GILEAD_TAF02562273	GILEAD_TAF02562273
DTX-401	HIV Medications and Treatments _ ViiV Healthcare	GILEAD_TAF02562274	GILEAD_TAF02562279
DTX-402	Laurus Labs _ Eight Roads	GILEAD_TAF02562280	GILEAD_TAF02562283
DTX-403	Medicines _ Gilead	GILEAD_TAF02562284	GILEAD_TAF02562292
DTX-404	Mylan Introduces Symfi Triple Combo Once-Daily HIV Treatment in the U.S._	GILEAD_TAF02562293	GILEAD_TAF02562294
DTX-405	New Drug Discovery _ Natco Pharma	GILEAD_TAF02562295	GILEAD_TAF02562295
DTX-406	newgenerics_emtriva_2020-0902	GILEAD_TAF02562296	GILEAD_TAF02562296
DTX-407	Products _ Janssen	GILEAD_TAF02562297	GILEAD_TAF02562316
DTX-408	Products and Medicines - Bristol Myers Squibb	GILEAD_TAF02562317	GILEAD_TAF02562324
DTX-409	Seven \$1 billion-plus drugs seen reaching market in 2016 _ Reuters	GILEAD_TAF02562325	GILEAD_TAF02562326
DTX-410	Teva Announces Exclusive Launch of Generic Viread in the United States	GILEAD_TAF02562327	GILEAD_TAF02562330
DTX-411	Teva Announces Launch of Generic Baraclude Tablets, 0.5mg and 1mg, in the United States	GILEAD_TAF02562331	GILEAD_TAF02562332

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-412	Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA (emtricitabine 200 mg_tenofovir disoproxil fumarate 300 mg) and ATRIPLA (efavirenz 600 mg_emtricitabine 200 mg_tenofovir disoproxil fumarate 300 mg) Tablets in the U.S.	GILEAD_TAF02562333	GILEAD_TAF02562343
DTX-413	Tybost(cobicistat) tablet	GILEAD_TAF02562344	GILEAD_TAF02562345
DTX-414	United States Generic Pharmaceuticals _ Lupin Pharma	GILEAD_TAF02562346	GILEAD_TAF02562347
DTX-415	USA - Macleods	GILEAD_TAF02562362	GILEAD_TAF02562363
DTX-416	us-fda-approves-gilead-sciences-emtriva	GILEAD_TAF02562364	GILEAD_TAF02562366
DTX-417	us-food-and-drug-administration-approves-descovy	GILEAD_TAF02562367	GILEAD_TAF02562370
DTX-418	us-food-and-drug-administration-approves-gileads-second	GILEAD_TAF02562371	GILEAD_TAF02562375
DTX-419	us-food-and-drug-administration-approves-gileads-vemlidy	GILEAD_TAF02562376	GILEAD_TAF02562379
DTX-420	TAF Revenue by Month_Updated	GILEAD_TAF02563092	GILEAD_TAF02563092
DTX-421	HBV NPA TRx Monthly Historical Data	GILEAD_TAF02563093	GILEAD_TAF02563093
DTX-422	HIV PrEP National Performance Tracker WE 02.26.2022	GILEAD_TAF02563094	GILEAD_TAF02563106
DTX-423	PrEP_HBV request_091721_2PM	GILEAD_TAF02563107	GILEAD_TAF02563112
DTX-424	RGMN NPA TRx Weekly Volume and Share	GILEAD_TAF02563113	GILEAD_TAF02563113
DTX-425	2018 First Generic Drug Approvals _ FDA	GILEAD_TAF02566412	GILEAD_TAF02566423
DTX-426	Tenofovir-update	HETERO_TAF_0222208	HETERO_TAF_0222208
DTX-427	Teneffovir Alafenamide Fumarate Process Development Report	MAC_TEN00031335	MAC_TEN00031449
DTX-428	2002 Approved Drug Products with Therapeutic Equivalents, 22nd Edition	DEF-TAF-HOFMANN-0003833	DEF-TAF-HOFMANN-0004880
DTX-429	2017 Approved Drug Products with Therapeutic Equivalents, 37th Edition	DEF-TAF-HOFMANN-0001874	DEF-TAF-HOFMANN-0003273
DTX-430	2022 Approved Drug Products with Therapeutic Equivalents, 42nd Edition	DEF-TAF-HOFMANN-0000001	DEF-TAF-HOFMANN-0001728
DTX-431	Acorda Therapeutics, Inc. v. Roxane Labs., Inc., 903 F.3d 1310 (Fed. Cir. 2018)	DEF-TAF-HOFMANN-0005090	DEF-TAF-HOFMANN-0005105
DTX-432	UBS Investment Research for Gilead Sciences, dated November 15, 2010	DEF-TAF-HOFMANN-0005106	DEF-TAF-HOFMANN-0005160
DTX-433	U.S. Patent No. 4,808,716	DEF-TAF-HOFMANN-0003825	DEF-TAF-HOFMANN-0003830
DTX-434	U.S. Patent No. 5,914,331	DEF-TAF-HOFMANN-0003357	DEF-TAF-HOFMANN-0003381
DTX-435	U.S. Patent No. 6,225,460	DEF-TAF-HOFMANN-0004968	DEF-TAF-HOFMANN-0005022
DTX-436	U.S. Patent No. 6,642,245	DEF-TAF-HOFMANN-0003382	DEF-TAF-HOFMANN-0003407
DTX-437	U.S. Patent No. 6,703,396	DEF-TAF-HOFMANN-0003408	DEF-TAF-HOFMANN-0003425

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-438	U.S. Patent No. 6,838,464	DEF-TAF-HOFMANN-0003426	DEF-TAF-HOFMANN-0003449
DTX-439	U.S. Patent No. 7,067,522	DEF-TAF-HOFMANN-0003450	DEF-TAF-HOFMANN-0003473
DTX-440	U.S. Patent No. 7,125,879	DEF-TAF-HOFMANN-0003474	DEF-TAF-HOFMANN-0003541
DTX-441	U.S. Patent No. 7,390,791	DEF-TAF-HOFMANN-0003274	DEF-TAF-HOFMANN-0003301
DTX-442	U.S. Patent No. 7,803,788	DEF-TAF-HOFMANN-0003302	DEF-TAF-HOFMANN-0003330
DTX-443	U.S. Patent No. 8,080,551	DEF-TAF-HOFMANN-0003542	DEF-TAF-HOFMANN-0003608
DTX-444	U.S. Patent No. 8,101,629	DEF-TAF-HOFMANN-0003609	DEF-TAF-HOFMANN-0003633
DTX-445	U.S. Patent No. 8,754,065	DEF-TAF-HOFMANN-0003331	DEF-TAF-HOFMANN-0003344
DTX-446	U.S. Patent No. 9,296,769	DEF-TAF-HOFMANN-0003345	DEF-TAF-HOFMANN-0003356
DTX-447	716 Patent Assignment Database	DEF-TAF-HOFMANN-0003831	DEF-TAF-HOFMANN-0003832
DTX-448	305 Patent Assignment Database	DEF-TAF-HOFMANN-0004899	DEF-TAF-HOFMANN-0004900
DTX-449	Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV	DEF-TAF-HOFMANN-0005183	DEF-TAF-HOFMANN-0005204
DTX-450	FDA-Approved HIV Medicines	DEF-TAF-HOFMANN-0003656	DEF-TAF-HOFMANN-0003660
DTX-451	U.S. Patent No. 6,225,460	DEF-TAF-HOFMANN-0005023	DEF-TAF-HOFMANN-0005089
DTX-452	Viread® FDA Approval Letter, 2001	DEF-TAF-HOFMANN-0001729	DEF-TAF-HOFMANN-0001733
DTX-453	Truvada® FDA Approval Letter, dated July 2012	DEF-TAF-HOFMANN-0005167	DEF-TAF-HOFMANN-0005179
DTX-454	Descovy® FDA Approval Letter, dated April 4, 2016	DEF-TAF-HOFMANN-0001794	DEF-TAF-HOFMANN-0001799
DTX-455	Odefsey® FDA Approval Letter, dated March 1, 2016	DEF-TAF-HOFMANN-0001734	DEF-TAF-HOFMANN-0001740
DTX-456	Vemlidy® FDA Approval Letter, dated November 10, 2016	DEF-TAF-HOFMANN-0001835	DEF-TAF-HOFMANN-0001842

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-457	Descovy® Supplemental Approval Letter, dated October 3, 2019	DEF-TAF-HOFMANN-0001828	DEF-TAF-HOFMANN-0001834
DTX-458	Descovy® Label, revised April 2016	DEF-TAF-HOFMANN-0001800	DEF-TAF-HOFMANN-0001827
DTX-459	Truvada® FDA Label, revised June 2020	DEF-TAF-HOFMANN-0003765	DEF-TAF-HOFMANN-0003802
DTX-460	Odefsey® FDA Label, revised September 2021	DEF-TAF-HOFMANN-0001741	DEF-TAF-HOFMANN-0001787
DTX-461	Vemlidy® FDA Label, revised September 2021	DEF-TAF-HOFMANN-0001843	DEF-TAF-HOFMANN-0001873
DTX-462	Apretude® FDA Label, revised December 2021	DEF-TAF-HOFMANN-0003674	DEF-TAF-HOFMANN-0003721
DTX-463	Descovy® Label, revised January 2022	DEF-TAF-HOFMANN-0003722	DEF-TAF-HOFMANN-0003764
DTX-464	Truvada FDA Approval, New Drug Application 021752	DEF-TAF-HOFMANN-0003803	DEF-TAF-HOFMANN-0003809
DTX-465	Center for Drug Evaluation and Research, Viread Admin Docs, Application No. 21-356	DEF-TAF-HOFMANN-0004901	DEF-TAF-HOFMANN-0004967
DTX-466	CDC Guidance for People Coinfected with HIV and Viral Hepatitis	DEF-TAF-HOFMANN-0003810	DEF-TAF-HOFMANN-0003812
DTX-467	CDC About PrEP (Pre-Exposure Prophylaxis)	DEF-TAF-HOFMANN-0005165	DEF-TAF-HOFMANN-0005166
DTX-468	CDC Basic Statistics for HIV	DEF-TAF-HOFMANN-0003644	DEF-TAF-HOFMANN-0003648
DTX-469	CDC HIV Risk and Prevention - Prevention as Treatment	DEF-TAF-HOFMANN-0003661	DEF-TAF-HOFMANN-0003664
DTX-470	Gilead's converting Truvada PrEP users to Descovy faster than expected: analyst	DEF-TAF-HOFMANN-0005180	DEF-TAF-HOFMANN-0005182
DTX-471	Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic	DEF-TAF-HOFMANN-0005161	DEF-TAF-HOFMANN-0005164
DTX-472	Hepatitis B Foundation: HIV/AIDS Coinfection	DEF-TAF-HOFMANN-0003817	DEF-TAF-HOFMANN-0003819
DTX-473	HIV.gov - Pre-Exposure Prophylaxis (PrEP)	DEF-TAF-HOFMANN-0003669	DEF-TAF-HOFMANN-0003673
DTX-474	HIV.gov - HIV Treatment Overview	DEF-TAF-HOFMANN-0003641	DEF-TAF-HOFMANN-0003643
DTX-475	HIV.gov - HIV Treatment as Prevention	DEF-TAF-HOFMANN-0003665	DEF-TAF-HOFMANN-0003668
DTX-476	Mayo Clinic - Hepatitis B Diagnosis	DEF-TAF-HOFMANN-0003820	DEF-TAF-HOFMANN-0003824

Trial Ex. No.	Description	Beg Bates	End Bates
DTX-477	Mayo Clinic - Hepatitis B Overview	DEF-TAF-HOFMANN-0003813	DEF-TAF-HOFMANN-0003816
DTX-478	Mayo Clinic - HIV/AIDS Diagnosis	DEF-TAF-HOFMANN-0003649	DEF-TAF-HOFMANN-0003655
DTX-479	Mayo Clinic - HIV/AIDS Overview	DEF-TAF-HOFMANN-0003634	DEF-TAF-HOFMANN-0003640
DTX-480	Differences between HIV-1 and HIV-2	DEF-TAF-HOFMANN-0001788	DEF-TAF-HOFMANN-0001793
DTX-481	Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries	DEF-TAF-HOFMANN-0005205	DEF-TAF-HOFMANN-0005208
DTX-482	FDA Summary Review Application 208215Orig1s000 (Descovy)		
DTX-483	FDA Summary Review Application 208464Orig1s000 (Vemlidy)		
DTX-484	FDA Summary Review Application 208351Orig1s000 (Odefsey)		
DTX-485	FDA Summary Review Application 207561Orig1s000 (Genvoya)		